Table 6.

Average individual level health gain associated with five-years of double therapy with (3%) and without (0%) discounting to potentially facilitate more informed patient-clinician discussions around medication use (the values at 0% discount rate are in brackets)

Five-year cumulative absolute risk strata	Quality-adjusted healthy months of life gained for the average cohort member from the offer of screening (intention-to-treat style of analysis)		Quality-adjusted healthy months of life gained for those who respond to the screening offer and commence treatment*
	Non-Māori	Māori	Non-Māori	Māori
>20%	3.5 (5.2)	2.9 (4.1)	4.9 (7.3)	4.1 (5.8)
>15, ≤20%	2.4 (3.7)	2.1 (3.1)	3.4 (5.3)	3.0 (4.4)
>10, ≤15%	1.6 (2.6)	1.5 (2.2)	2.3 (3.6)	2.1 (3.1)
>5, ≤10%	0.8 (1.4)	0.9 (1.3)	1.2 (1.9)	1.2 (1.9)
>0, ≤5%	0.4 (0.7)	0.5 (0.7)	0.6 (1.0)	0.7 (1.0)

^*Albeit with the reduction in adherence as in the base-case model of 22.5% over the five-year period of treatment.